EGFR-mutant NSCLC transforming to neuroendocrine tumors after TKI treatment are usually treated with platinum etoposide, a regiment that yields a clinical response rate of 54% in a retrospective series [79]. Here, EGFR is linked to neuroendocrine neoplasm.